Paclitaxel-loaded glyceryl palmitostearate nanoparticles: In vitro release and cytotoxic activity

Journal of Drug Targeting

Volumn 17, Issue 4, 2009, Pages 304-310

  Shenoy, Vikram S ^a   Gude, Rajiv P ^b   Ramchandra Murthy, Rayasa S ^a  

^a M S UNIVERSITY OF BARODA   (India)

^b TATA MEMORIAL HOSPITAL   (India)

Author keywords

B16F10 cell lines; Chemosensitivity assay; Gylceryl palmitostearate; Paclitaxel; Solid lipid nanoparticles

Indexed keywords

GLYCEROL PALMITOSTEARATE; PACLITAXEL;

ANIMAL CELL; ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG RELEASE; ENCAPSULATION; FLOCCULATION; IN VITRO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PH MEASUREMENT; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL PROLIFERATION; DIGLYCERIDES; DRUG CARRIERS; HYDROGEN-ION CONCENTRATION; MELANOMA, EXPERIMENTAL; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE;

EID: 70749149625     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860902737938     Document Type: Article

References (30)

1. Danino D, Talmon Y, Zana R. (1997). Vesicle-to-micelle transformation in systems containing dimeric surfactants. J Colloid Interface Sci, 185, 84-93.
2. Fidler IJ. (1973). Selection of successive tumor lines for metastasis. Nat New Biol, 242, 148-149.
3. Freitas C, Muller RH. (1999). Stability determination of solid lipid nanoparticles (SLN) in aqueous dispersion after addition of electrolyte. J Microencapsul, 16, 59-71.
4. Giacomo F, Laura M, Domenico S, Gennara C, Gaetano G. (2005). Solid lipid nanoparticles containing tamoxifen characterization and in vitro antitumoral activity. Drug Deliv, 12, 385-392.
5. Gude RP, Binda MM, Prasas HL, Andres JP, Klein-Santo R, Bonfil D. (1996). Studies on mechanisms responsible for inhibition of experimental metastasis of B16F10 murine melanoma by Pentoxifyline. J Biomed Sci, 6, 133-141.
6. Gude RP, Jadhav MG, Rao SGA, Jagtap AG. (2002). Effects of niosomal cisplatin and combination of the same with theophylline and with activated macrophages in murine B16F10 melanoma model. Cancer Biother Radiopharm, 17(2), 183-192.
7. Hansen MB, Nielsen SE, Berg K. (1989). Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods, 119, 203-210.
8. Heiati H, Phillips NC, Tawashi R. (1996). Evidence for phospholipid bilayer formation in solid lipid nanoparticles formulated with phospholipid and triglyceride. Pharm Res, 13, 1406-1410.
9. Jong-Ho K, Yoo-Shin K, Sungwon K, Jae HP, Kwangmeyung K, Kuiwon C, Hesson C, Seo YJ, Rang-Woon P, In-San K, Ick CK. (2006). Hydrophobically modified glycol chitosan nanoparticles as carriers for Paclitaxel. J Control Release, 111, 228-234.
10. Korsenmeyer RW, Gurny R, Doelkar, E, Buri P, Peppas NA. (1983). Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm, 15, 23-25.
11. Mazzo D, Nguyen Huu JJ, Pagniez S, Denis P. (1997). Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials. Am J Health-Syst Pharm, 54, 566-569.
12. Miglietta A, Cavalli R, Bocca C, Gabriel L, Gasco MR. (2000). Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm, 210(1-2), 61-67.
13. Mi-Kyung L, Soo-Jeong L, Chong-Kook K. (2007). Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials, 28(12), 2137-2146.
14. Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods, 65, 55-63.
15. Muller RH, Maassen S, Weyhers H, Mehnert W. (1996). Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target, 4, 161-170.
16. Muller RH, Maassen S, Schwarz C, Mehnert W. (1997). Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes. J Control Release, 47, 261-269.
17. Muller RH, Mader K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm, 50(1), 161-177.
18. Porter CJH, Moghimi SM, Illum L, Davis SS. (1992). The polyoxyethylene/ polyoxypropylene block co-polymer poloxamer 407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett, 305, 62-66.
19. Serpe L, Catalano MG, Cavalli R, Ugazio E, Bosco O, Canaparo R, Muntoni E, Frairia R, Gasco MR, Eandi M, Zara GP. (2004). Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm, 58, 673-680.
20. Singla AK, Garg A, Aggarwal D. (2002). Paclitaxel and its formulations. Int J Pharm, 235(1-2), 179-192.
21. Spencer CM, Faulds D. (1994). Paclitaxel: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs, 48, 782-794.
22. Stolnik S, Illum L, Davis SS. (1995). Long circulating microparticulate drug carriers. Adv Drug Del Rev, 16, 195-214.
23. Storm G, Belliot SO, Daemen T, Lasic DD. (1995). Surface modification of nanoparticles to oppose uptake by mononuclear phagocyte system. Adv Drug Del Rev, 17, 31-48.
24. Subramanian N, Murthy RSR. (2003). Use of electrolyte induced flocculation technique for an in vitro steric stability study of steric stabilized liposome formulations. Pharmazie, 59, 74-76.
25. Thipgen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. (1994). Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A gynaecologic oncology group study. J Clin Oncol, 12, 1748-1753.
26. Videira M, Florindo HF, Gouveia LF, Lobato MR, Almeida AJ. (2005). Triglyceride nanoparticles as potential carriers for paclitaxel. In: Proceedings of the 15th International Symposium on Microencapsulation, September 18-21, Parma, Italy.
27. Westesen K, Bunjes H, Koch MHJ. (1997). Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release, 48, 223-236.
28. Yang S, Zhu J, Lu Y, Liang B, Yang C. (1999a). Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res, 16(5), 751-757.
29. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. (1999b). Body distribution in mice of intravenous injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release, 59(3), 299-307.
30. Yuan H, Miao J, Du Y-Z, You J, Hu F-Q, Zeng S. (2008). Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm, 348(1-2), 137-145.